Medicines and Healthcare products Regulatory Agency
Regulatory Agency
- MHRA guidance on Coronavirus (COVID-19)
- MHRA guidance on transition
- Drug and device alerts
- Drug Safety Update
- Yellow Card: Report a problem with a medicine or medical device
- Marketing authorisations and licensing guidance
- Patient information leaflets and summaries of product characteristics
- Public assessment reports
- Medical devices regulation and safety
- Contact MHRA
- All MHRA services and information
Featured
Collection
MHRA post-transition period information
Guidance for industry and organisations to follow from 1 January 2021.
Collection
MHRA guidance on coronavirus (COVID-19)
We are producing guidance and information for industry, healthcare professionals and patients covering the coronavirus (COVID-19) outbreak.
Press release
One pharmacist’s report helps safer use of inhalers in the UK
Reporting suspected side effects or incidents to the Yellow Card scheme supports the safe use of medical products for everyone
Press release
Stephen Lightfoot to become Chair
Stephen Lightfoot will become Chair of the Medicines and Healthcare products Regulatory Agency (MHRA) from 1 September 2020.
Guidance
How tests and testing kits for coronavirus (COVID-19) work
The different types of tests and testing kits for COVID-19, and the specifications for manufacturers.
News story
MHRA response statement to IMMDS Review report publication
Today’s publication of the Independent Medicines and Medical Devices Safety Review is of profound importance for the MHRA, since the safety of the public is our first priority.
Latest from the Medicines and Healthcare products Regulatory Agency
What the Medicines and Healthcare products Regulatory Agency does
The Medicines and Healthcare products Regulatory Agency regulates medicines, medical devices and blood components for transfusion in the UK.
MHRA is an executive agency, sponsored by the Department of Health and Social Care.
Follow us
Documents
Policy papers and consultations
- Consultation on the application of Analytical Quality by Design (AQbD) principles to pharmacopoeial standards for medicines
- How should we engage and involve patients and the public in our work
Transparency and freedom of information releases
- Medicines and Healthcare products Regulatory Agency senior officials' expenses from January to March 2020
- Medicines and Healthcare products Regulatory Agency senior officials' expenses from October to December 2019
Our management
Contact MHRA
General enquiries
10 South Colonnade
London
E14 4PU
United Kingdom
Telephone
020 3080 6000
Fax
020 3118 9803
Please get in touch with us by phone or email during the coronavirus (COVID-19) response period.
In line with the Government’s advice, our building at 10 South Colonnade closed at 5pm on Friday 27 March.
Office hours are Monday to Friday, 9am to 5pm.
Media enquiries
MHRA
10 South Colonnade
London
E14 4PU
United Kingdom
During office hours:
020 3080 7651 (08:30 - 17:00)
Out of office hours:
07770 446 189 (17:00 - 08:30)
Office hours are Monday to Friday, 8:30am to 5pm. For real-time updates including the latest press releases and news statements, see our Twitter channel at https://www.twitter.com/mhragovuk
Make an FOI request
- Read about the Freedom of Information (FOI) Act and how to make a request.
- Check our previous releases to see if we’ve already answered your question.
- Make a new request by contacting us using the details below.
Freedom of Information
Corporate information
Jobs and contracts